Background Little is known about the epidemiology of eczema in adults. The goal of this
study was to determine the prevalence of and associations with adult eczema in the United …

Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha,
inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important …

AD is a chronic inflammatory skin disease affecting both children and adults. AD is associated
with a substantial public health burden secondary to high prevalence in many regions and …

Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food
allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), …

Objective Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with substantial
patient and population burdens. A number of comorbid health problems occur in patients …

Importance Disability secondary to skin conditions is substantial worldwide. The Global
Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4
and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. …

Background The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in
the United States population is not well established. Objective To elucidate the patient burden …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with atopic/…